{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:30:31Z","timestamp":1778646631328,"version":"3.51.4"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Refractory chronic migraine is a common and debilitating neurologic condition, affecting over 8 million people in the United States. It is associated with billions of dollars in lost productivity annually. Novel medical (anti\u2013calcitonin gene-related peptide antibodies) and surgical treatment modalities have emerged for chronic migraine in recent years. The current study investigated the cost-utility of surgical versus medical management of refractory chronic migraine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A Markov cohort analysis using hybrid Monte Carlo patient simulation was performed to compare surgical decompression versus erenumab for the treatment of refractory chronic migraine in adults. Both societal and payer perspectives were considered. Primary model outcomes included incremental cost-effectiveness ratio, or cost per quality-adjusted life-year gained.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Over a 5-year period, migraine surgery was associated with an increase of 0.2 quality-adjusted life-year per patient when compared to erenumab. In terms of costs, the results demonstrated a $19,337 decrease in direct medical costs and a $491 decrease in indirect costs (productivity lost) for the surgery cohort compared to erenumab. Because surgery improved quality of life and decreased costs compared to erenumab, even when considering revision surgery needs, surgery was the overall dominant treatment in terms of cost-effectiveness. Sensitivity analyses demonstrated that surgery was cost-effective compared to erenumab when patients required therapy for at least 1 year.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Surgical deactivation of migraine trigger sites may pose a cost-effective approach to treating refractory chronic migraine in adults. This is especially the case when patients are anticipated to require therapy for more than 1 year.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/prs.0000000000009048","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T15:01:25Z","timestamp":1647874885000},"page":"1187-1196","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["A Markov Analysis of Surgical versus Medical Management of Chronic Migraines"],"prefix":"10.1097","volume":"149","author":[{"given":"Pooja S.","family":"Yesantharao","sequence":"first","affiliation":[{"name":"From the Departments of Plastic and Reconstructive Surgery and Neurosurgery, Johns Hopkins Hospital; and Department of Biomedical Engineering and the Institute for NanoBioTechnology, Johns Hopkins University."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Departments of Plastic and Reconstructive Surgery and Neurosurgery, Johns Hopkins Hospital; and Department of Biomedical Engineering and the Institute for NanoBioTechnology, Johns Hopkins University."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Klifto","sequence":"additional","affiliation":[{"name":"From the Departments of Plastic and Reconstructive Surgery and Neurosurgery, Johns Hopkins Hospital; and Department of Biomedical Engineering and the Institute for NanoBioTechnology, Johns Hopkins University."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salih","family":"Colakoglu","sequence":"additional","affiliation":[{"name":"From the Departments of Plastic and Reconstructive Surgery and Neurosurgery, Johns Hopkins Hospital; and Department of Biomedical Engineering and the Institute for NanoBioTechnology, Johns Hopkins University."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Lee","family":"Dellon","sequence":"additional","affiliation":[{"name":"From the Departments of Plastic and Reconstructive Surgery and Neurosurgery, Johns Hopkins Hospital; and Department of Biomedical Engineering and the Institute for NanoBioTechnology, Johns Hopkins University."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sashank K.","family":"Reddy","sequence":"additional","affiliation":[{"name":"From the Departments of Plastic and Reconstructive Surgery and Neurosurgery, Johns Hopkins Hospital; and Department of Biomedical Engineering and the Institute for NanoBioTechnology, Johns Hopkins University."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"R1-20250501","doi-asserted-by":"crossref","first-page":"g1416","DOI":"10.1136\/bmj.g1416","article-title":"Chronic migraine.","volume":"348","author":"Schwedt","year":"2014","journal-title":"BMJ"},{"key":"R2-20250501","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/head.13613","article-title":"Life with migraine: Effects on relationships, career, and finances from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.","volume":"59","author":"Buse","year":"2019","journal-title":"Headache"},{"key":"R3-20250501","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/head.13342","article-title":"Identifying natural subgroups of migraine based on comorbidity and concomitant condition profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.","volume":"58","author":"Lipton","year":"2018","journal-title":"Headache"},{"key":"R4-20250501","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/head.13021","article-title":"Psychological factors associated with chronic migraine and severe migraine-related disability: An observational study in a tertiary headache center.","volume":"57","author":"Seng","year":"2017","journal-title":"Headache"},{"key":"R5-20250501","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/head.13421","article-title":"Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine.","volume":"58","author":"Silberstein","year":"2018","journal-title":"Headache"},{"key":"R6-20250501","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.55.5.629","article-title":"Migraine, quality of life, and depression: A population-based case-control study.","volume":"55","author":"Lipton","year":"2000","journal-title":"Neurology"},{"key":"R7-20250501","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1526-4610.2002.04262.x","article-title":"The economic impact of migraine: An analysis of direct and indirect costs.","volume":"42","author":"Edmeads","year":"2002","journal-title":"Headache"},{"key":"R8-20250501","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/head.13275","article-title":"Direct and indirect healthcare resource utilization and costs among migraine patients in the United States.","volume":"58","author":"Bonafede","year":"2018","journal-title":"Headache"},{"key":"R9-20250501","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/PRS.0b013e318244217a","article-title":"A socioeconomic analysis of surgical treatment of migraine headaches.","volume":"129","author":"Faber","year":"2012","journal-title":"Plast Reconstr Surg"},{"key":"R10-20250501","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jech.46.4.443","article-title":"Impact of headache on sickness absence and utilisation of medical services: A Danish population study.","volume":"46","author":"Rasmussen","year":"1992","journal-title":"J Epidemiol Community Health"},{"key":"R12-20250501","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s10194-019-1040-x","article-title":"Identifying and managing refractory migraine: Barriers and opportunities?","volume":"20","author":"D\u2019Antona","year":"2019","journal-title":"J Headache Pain"},{"key":"R13-20250501","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2377-11-94","article-title":"Refractory migraine in a headache clinic population.","volume":"11","author":"Irimia","year":"2011","journal-title":"BMC Neurol"},{"key":"R14-20250501","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"R15-20250501","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"R16-20250501","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"R17-20250501","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial.","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"R18-20250501","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/PRS.0b013e3181adcf6a","article-title":"A placebo-controlled surgical trial of the treatment of migraine headaches.","volume":"124","author":"Guyuron","year":"2009","journal-title":"Plast Reconstr Surg"},{"key":"R20-20250501","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/PRS.0000000000006270","article-title":"The cutting edge of headache surgery: A systematic review on the value of extracranial surgery in the treatment of chronic headache.","volume":"144","author":"Bink","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"R21-20250501","doi-asserted-by":"crossref","first-page":"e2291","DOI":"10.1097\/GOX.0000000000002291","article-title":"Migraine surgery.","volume":"7","author":"Gfrerer","year":"2019","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R22-20250501","doi-asserted-by":"crossref","first-page":"187e","DOI":"10.1097\/PRS.0000000000007020","article-title":"A comprehensive review of surgical treatment of migraine surgery safety and efficacy.","volume":"146","author":"Hatef","year":"2020","journal-title":"Plast Reconstr Surg"},{"issue":"Suppl 2","key":"R23-20250501","doi-asserted-by":"crossref","first-page":"131S","DOI":"10.1097\/PRS.0000000000000661","article-title":"A review of current evidence in the surgical treatment of migraine headaches.","volume":"134","author":"Janis","year":"2014","journal-title":"Plast Reconstr Surg"},{"key":"R24-20250501","doi-asserted-by":"crossref","first-page":"e1270","DOI":"10.1097\/GOX.0000000000001270","article-title":"Targeted peripheral nerve-directed onabotulinumtoxin A injection for effective long-term therapy for migraine headache.","volume":"5","author":"Janis","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R25-20250501","doi-asserted-by":"crossref","first-page":"401e","DOI":"10.1097\/PRS.0000000000006480","article-title":"Cost-effectiveness of long-term, targeted onabotulinumtoxinA versus peripheral trigger site deactivation surgery for the treatment of refractory migraine headaches.","volume":"145","author":"Schoenbrunner","year":"2020","journal-title":"Plast Reconstr Surg"},{"key":"R26-20250501","first-page":"531","article-title":"Cost of migraine management: A pharmacoeconomic overview.","volume":"4","author":"Rapoport","year":"1998","journal-title":"Am J Manag Care"},{"key":"R27-20250501","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0025-6196(11)60562-4","article-title":"The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research.","volume":"84","author":"Burton","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"R28-20250501","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4065\/76.11.1093","article-title":"Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine.","volume":"76","author":"Lofland","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"R29-20250501","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1526-4610.2005.05182.x","article-title":"Cost-effectiveness of topiramate in migraine prevention: Results from a pharmacoeconomic model of topiramate treatment.","volume":"45","author":"Brown","year":"2005","journal-title":"Headache"},{"key":"R30-20250501","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"R31-20250501","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"key":"R32-20250501","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/PRS.0000000000001322","article-title":"A prospective randomized outcomes comparison of two temple migraine trigger site deactivation techniques.","volume":"136","author":"Guyuron","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R33-20250501","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/PRS.0b013e3181fed456","article-title":"Five-year outcome of surgical treatment of migraine headaches.","volume":"127","author":"Guyuron","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"R34-20250501","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/2277-9175.186994","article-title":"A comparison of outcome of medical and surgical treatment of migraine headache: In 1 year follow-up.","volume":"5","author":"Omranifard","year":"2016","journal-title":"Adv Biomed Res"},{"key":"R35-20250501","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1097\/SCS.0000000000004078","article-title":"Surgical management of migraine headache.","volume":"29","author":"Jose","year":"2018","journal-title":"J Craniofac Surg"},{"issue":"Suppl 1","key":"R36-20250501","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/SAP.0000000000000697","article-title":"Experience of surgical treatment for occipital migraine in Taiwan.","volume":"76","author":"Lin","year":"2016","journal-title":"Ann Plast Surg"},{"key":"R37-20250501","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1097\/SCS.0000000000001353","article-title":"Frontal endoscopic myotomies for chronic headache.","volume":"26","author":"Edoardo","year":"2015","journal-title":"J Craniofac Surg"},{"key":"R38-20250501","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0333102418796842","article-title":"Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives.","volume":"38","author":"Sussman","year":"2018","journal-title":"Cephalalgia"},{"key":"R39-20250501","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/0002-9343(82)90787-2","article-title":"A convenient approximation of life expectancy (the \u201cDEALE\u201d): II. Use in medical decision-making.","volume":"73","author":"Beck","year":"1982","journal-title":"Am J Med"},{"key":"R40-20250501","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0333102411410610","article-title":"The International Burden of Migraine Study (IBMS): Study design, methodology, and baseline cohort characteristics.","volume":"31","author":"Payne","year":"2011","journal-title":"Cephalalgia"},{"key":"R41-20250501","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.3390\/ijerph17114126","article-title":"Clinical reasoning behind non-pharmacological interventions for the management of headaches: A narrative literature review.","volume":"17","author":"Fern\u00e1ndez-de-las-Pe\u00f1as","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"R42-20250501","first-page":"3","article-title":"An analysis of risk factors and adverse events in ambulatory surgery.","volume":"1","author":"Kent","year":"2014","journal-title":"Ambulatory Anesth"},{"key":"R43-20250501","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/PRS.0000000000005353","article-title":"Therapeutic role of fat injection in the treatment of recalcitrant migraine headaches.","volume":"143","author":"Guyuron","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"R44-20250501","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/13696998.2018.1457533","article-title":"Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: A US societal perspective.","volume":"21","author":"Lipton","year":"2018","journal-title":"J Med Econ"},{"key":"R45-20250501","doi-asserted-by":"crossref","first-page":"NP462","DOI":"10.1093\/asj\/sjz069","article-title":"Cost-utility analysis of surgical decompression relative to injection therapy for chronic migraine headaches.","volume":"39","author":"Shauly","year":"2019","journal-title":"Aesthet Surg J"},{"key":"R46-20250501","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1177\/0333102411425960","article-title":"Costs associated with outpatient, emergency room and inpatient care for migraine in the USA.","volume":"31","author":"Insinga","year":"2011","journal-title":"Cephalalgia"}],"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000009048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:16:13Z","timestamp":1746144973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000009048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/prs.0000000000009048","relation":{},"ISSN":["0032-1052"],"issn-type":[{"value":"0032-1052","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,18]]}}}